TTrialPathMatch Me to Trials
← Back to trials
RecruitingInsomniaHypnotic Dependence

Enhancing Hypnotic Medication Discontinuation in Primary Care

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Many individuals with insomnia seek treatment in primary care settings, where they often receive prescription hypnotic medications as their first and sometimes only treatment. However, extended use of these medications can lead to reliance and increased health risks, such as falls and cognitive impairments. While evidence-based approaches like physician-supervised medication tapering exist, they're not widely available in primary care or other medical clinics. Most primary care providers are willing to explore non-drug treatments like cognitive behavioral therapy for insomnia (CBTI), but accessing such treatments can be challenging outside of specialized sleep centers. This gap between research and practice underscores the need for cost-effective interventions to manage insomnia and help patients reduce their reliance on hypnotics in primary care. In response to this need, the project aims to conduct a large randomized trial comparing a combined digital CBT (dCBTI) and medication tapering intervention with medication tapering alone. We'll recruit 250 patients reliant on hypnotics across collaborating clinics and the general public . The main goal is to assess the effectiveness of dCBTI+SMT compared to SMT alone in reducing hypnotic use and improving insomnia symptoms. Additionally, we'll evaluate factors affecting the adoption and implementation of these interventions at the patient, provider, and system levels. This information will inform future implementation strategies to disseminate effective treatments in primary care. Furthermore, we'll gather data to identify which patients benefit most from dCBTI+SMT. Overall, this study will provide valuable insights into the feasibility, clinical utility, and acceptability of these interventions in managing insomnia and reducing reliance on hypnotic medications in medical settings. Ultimately, this project represents a crucial first step toward making accessible and cost-effective strategies available to improve the quality of life for millions of chronic users of sleep aids.

Sponsor: National Jewish Health

You may not qualify if…

  • ✕ Appendix A: Eligible Medications
  • ✕ Zolpidem (Ambien, Ambien CR)
  • ✕ Lorazepam (Ativan)
  • ✕ Clonazepam (Klonopin)
  • ✕ Eszopiclone (Lunesta)
  • ✕ Temazepam (Restoril)
  • ✕ Zaleplon (Sonata)
  • ✕ Alprazolam (Xanax)

Where it's recruiting

Colorado

Denver

Source: ClinicalTrials.gov · NCT06435520 · last updated 2026-11-12

Enhancing Hypnotic Medication Discontinuation in Primary Care · TrialPath